安替可胶囊治疗消化系统肿瘤的文献分析

Antike Capsule for Treatment of Digestive System Tumors:Literature Analysis

目的：了解和评价安替可胶囊在消化系统肿瘤中的应用情况。方法：利用中国知网（CNKI），采用跨库高级检索，以“安替可胶囊”与“食管癌”、“肝癌”为检索词，按主题检索，时间设定为1997年1月-2012年12月，筛选有关文献题录数据，详细记录文献中入组患者的病种、性别与年龄分布，安替可胶囊与对照组的处理方法、观察指标、疗效及不良反应等，采用文献计量法，利用Excel和Access数据软件对数据进行处理。结果：共检索到临床应用相关文献11篇，共1987例患者，其中食管癌1310例，肝癌531例。安替可胶囊联合放疗治疗食管癌的完全缓解率为33．33％-88．46％、1年生存率为68．9％-76．67％；对于晚期食管癌的疗效与单纯化疗相当（疾病控制率：76．6％vs．70．2％）。在肝癌治疗方面，安替可胶囊联合介入治疗肝癌的缓解率为50．7％（介入组为31．7％）、甲胎蛋白转阴率为50．8％（介入组为21．8％）；安替可胶囊与金龙胶囊相比疗效相当，肿瘤有效率为18．84％（金龙胶囊组为14．71％），且症状改善更为明显（82．61％vs．60．29％）；安替可胶囊与化疗相比，疾病控制率为72．97％（化疗组为60．0％）。结论：安替可胶囊在消化系统肿瘤中应用广泛，抗肿瘤作用确切，同时还具有维护血象、提高免疫功能和改善生活质量的作用，不良反应发生率低且程度轻，适宜临床推广应用。

OBJECTIVE：To investigate and evaluate the application of Antike Capsules in the treatment of digestive system tumors. METHODS： By using Chinese Journal Full-text Database （CNKI） for cross-database advanced search, with ＂Antike capsules＂, ＂esophageal cancer＂ and ＂liver cancer＂ as index terms to search for the bibliographical reference data of pertinent literature （indexed from January 1997 to December 2012）. The data including disease type, gender and age distribution, management （treatment）, outcome measures, efficacy and side effects of both Antike Capsules-treatment group and the control group were recorded in detail. By quantitative measure, the data processing was performed using Excel and Access database software. RESULTS： A total of 11 full-text papers involving a total of 1 987 patients were retrieved, ofwhom 1 310 were esophageal cancer cases and 531 were liver cancer cases. A complete remission rate of 33.33%-88.46% and 1-year survival rate of 68.9%-76. 67% were achieved in those patients with esophageal cancer after treatment with Antike Capsules combined with radiotherapy; however, the curative efficacy was similar between those receiving combined therapy and those receiving chemotherapy alone （disease control rate： 76. 6% vs. 70. 2% ） for patients with advanced esophageal cancer. In the treatment of liver cancer, the patients receiving Antike Capsules plus interventional therapy showed a remission rate of 50. 7% （31.7% in the intervention group） and AFP negative-returning rate of 50. 8% （21.8% in the intervention group）; as compared with Jinlong Capsules, the curative efficacy was similar between the two, with effective rate of 18. 84% vs. 14. 71% for tumor, yet the Antike Capsules plus interventional therapy -treated group was more significant in improvement of symptoms （82. 61% vs. 60. 29% ）, and compared with chemotherapy alone group, the disease control rate was 72. 97% vs. 60. 0%. CONCLUSION ： With proved anti-tumor efficacy yet low incidence and mild in severity of side effects as well as the action of maintaining hemogram and improving immune function and quality of life, Antike Capsules have been widely used in the treatment of digestive system tumors, and the clinical use of which is thus worthy of clinical recommendation.